

Contents lists available at ScienceDirect

Journal of Cardiology Cases



journal homepage: www.elsevier.com/locate/jccase

Case Report

Extremely rare rapid development of a papillary fibroelastoma on the left ventricular anterior papillary muscle



Ami Niwano (MT)^a, Haruka Sasaki (MD, PhD)^{b,*}, Hiroyuki Takaoka (MD, PhD, FJCC)^b, Kenji Kawasaki (MT, PhD)^a, Kentaro Atarashi (MD, PhD)^e, Jun-Ichiro Ikeda (MD, PhD)^d, Goro Matsumiya (MD, PhD)^c, Kazuyuki Matsushita (MD, PhD)^a, Yoshio Kobayashi (MD, PhD, FJCC)^b

^a Department of Laboratory Medicine, Chiba University Hospital, Chiba, Japan

^b Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan

^c Department of Cardiovascular Surgery, University of Chiba, Chiba, Japan

^d Department of Diagnostic Pathology, Chiba University Graduate School of Medicine, Chiba, Japan

e Department of Cardiovascular Medicine, Chiba Central Medical Center, Chiba, Japan

ARTICLE INFO

Article history: Received 17 June 2022 Received in revised form 30 July 2022 Accepted 8 August 2022

Keywords: Papillary fibroelastoma Left ventricular papillary muscle Rapid growth

ABSTRACT

Papillary fibroelastoma (PFE) is a rare, slow-growing cardiac tumor. We encountered an 80-year-old man with PFE accidentally revealed by transthoracic echocardiography (TTE) to evaluate cardiac function before a non-cardiac operation. A 10-mm mass lesion adhered to the anterior papillary muscle of the left ventricle, which had not been detected with TTE performed nine months before. Emergency cardiac surgery to remove the mass was performed, and the mass was diagnosed as a PFE. The PFE grew to 10 mm in a maximum of 9 months; to our knowledge, this is the fastest growth of PFE in the left ventricle reported to date.

Learning objective: Papillary fibroelastoma (PFE) is a rare, slow-growing cardiac tumor. The surgical indication of PFE is sometimes controversial. The rapid growth of PFE might be considered as a criterion for surgery because this might result in the rapid progression of symptoms and complications.

© 2022 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Introduction

Primary cardiac tumors are exceedingly rare, with a reported incidence of 0.021 % in autopsy cases. Approximately 8 % of these are papillary fibroelastoma (PFE) [1,2]. In general, PFE is a slow-growing tumor that is dominantly attached to cardiac valves. We encountered a male patient with PFE in the left ventricle, which grew to 10 mm in a maximum of 9 months.

Case report

The patient was an 80-year-old man who was referred to the otorhinolaryngology department of our hospital for parathyroidectomy for hyperparathyroidism. He was diagnosed with angina pectoris and underwent a percutaneous coronary intervention for a proximal segment of the left anterior descending artery at age 75 years.

Transthoracic echocardiography (TTE) as part of the preoperative cardiac assessment revealed a 10-mm mass lesion attached to the


anterior papillary muscle of the left ventricle (Fig. 1A, B, Video 1), which had not been observed 9 months previously (Fig. 1C, D). The mass was pedunculated and mobile with an irregular surface.

Physical examination was as follows: body temperature 36.7 °C. heart rate 58 beats/min. and blood pressure 154/76 mmHg. Cardiac murmur was not detected. The chest radiograph was normal while the electrocardiogram showed a complete right bundle branch block and left axis deviation. Laboratory tests revealed no increased inflammatory response or coagulation abnormality, and a C-reactive protein level of 0.02 mg/l, white blood cell count of 4400/µl, and D-dimer level of 0.6 µg/ml. No bacterium was detected in blood cultures. Cardiac contrast computed tomography (CT) showed a 10-mm mass on the left ventricular anterior papillary muscle (Fig. 2A, B), and no significant stenosis of coronary arteries was suspected. A retrospective review of past CT data showed the presence of the mass in the left ventricle lumen in contrast CT without electrocardiographic (ECG) gating with a slice thickness of 5 mm performed almost one month before (Fig. 2C, Video 2A), but not in contrast CT without ECG gating with a slice thickness of 1 mm performed under the same protocol seven months before (Fig. 2D, Video 2B).

Considering the risk of embolism, emergency cardiac surgery to remove the mass was performed. The surgery was performed via a


^{*} Corresponding author at: Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 2608677, Japan. *E-mail address:* ayta0206@chiba-u.jp (H. Sasaki).


^{1878-5409/© 2022} Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.



median sternotomy approach under cardiopulmonary bypass. The tumor of the left ventricle was resected via the mitral valve via an incision through the left atrium. The $10 \times 6 \times 5$ mm mass was resected, with no thrombus attached. Pathological examination revealed papillary

lesions with a vitreous interstitium covered with endothelial cells (Fig. 3), and the mass was diagnosed as PFE. The postoperative course was uneventful, and the patient was discharged eight days after the operation. No recurrence was observed in TTE two years later.





Discussion

In general, PFE is recognized as a slow-growing tumor. A previous study reported that the average growth rate of PFE was 0.5 \pm 0.9 mm/ year [3]. In our present case, PFE had not been observed in the previous TTE performed nine months before. Given a reported sensitivity and specificity of TTE for the detection of PFE ≥2 mm of 88.9 % and 87.8 %, respectively, it is unlikely that the PFE had been overlooked at that time [4], suggesting in turn the high possibility that it had grown to 10 mm in a maximum of 9 months. Currently, no factors are available to predict the growth rate of PFE [3], and the determinants of growth are unclear. A few reports have described the rapid development of PFE on valve tissue, one of which was due to thrombus attachment [5,6]. In our present case, however, no thrombus was attached to the resected mass, and its size of 10 mm was similar to that on evaluation of preoperative imaging. We, therefore, consider that the tumor grew relatively rapidly. PFE is a rare lesion and PFE in the left ventricle is rarer still. Moreover, no report has yet described a fast-growing PFE in the left ventricle. We, therefore, consider that this case is unique.

The etiology of PFE has been discussed in various ways, including hamartomas, acquired reactive lesions, and the possibility of gene mutations [7], but no conclusive answer has yet been obtained. The possibility that PFE may also be produced by endocardial damage due to intracardiac turbulence or hyperplasia due to fibrin deposition has also been proposed, which would suggest that PFE can occur anywhere in the heart [8]. The majority of cases occur on the valve tissue, and cases occurring in the left ventricle are rare [9]. The association between tumor position and growth rate is still unknown.

Patients with PFE are at risk of cerebral embolic events, angina, intestinal ischemia, heart failure due to valvular dysfunction, and sudden death. When PFE occurs in the left ventricle, as in this case, left ventricular obstruction may occur. The current management of PFE is surgical resection for symptomatic patients but controversy remains, especially regarding asymptomatic patients. Tumor mobility has been reported to predict a poor prognosis [9], and so might be a criterion for surgery in asymptomatic patients. An effect of tumor growth rate on the risk of embolic events has not been proved [3]; nevertheless, we consider that rapid growth should be recognized as a criterion for surgery because this might result in the rapid progression of symptoms and complications.

Conclusions

We experienced a male with PFE on the left ventricular anterior papillary muscle which had not been detected by TTE nine months previously. The PFE was resected as an emergency. The postoperative course was uneventful, and no recurrence was observed on TTE two years later.

Supplementary data to this article can be found online at https://doi. org/10.1016/j.jccase.2022.08.010.

Declaration of competing interest

The authors declare that there is no conflict of interest.

References

- [1] Reynen K. Frequency of primary tumors of the heart. Am J Cardiol 1996;77:107.
- [2] Burke A, Virmani R. Tumors of the heart and great vessels. Atlas of tumor pathology. 3rd seriesWashington DC: Armed Forces Institute of Pathology; 1996. p. 1–11.
- [3] Kurmann RD, El-Am EA, Sorour AA, Lee AT, Scott CG, Bois MC, Maleszewski JJ, Klarich KW. Papillary fibroelastoma growth: a retrospective follow-up study of patients with pathology-proven papillary fibroelastoma. J Am Coll Cardiol 2021;77:2154–5.
- [4] Sun JP, Asher CR, Yang XS, Cheng GG, Scalia GM, Massed AG, Griffin BP, Ratliff NB, Stewart WJ, Thomas JD. Clinical and echocardiographic characteristics of papillary fibroelastomas: a retrospective and prospective study in 162 patients. Circulation 2001;103:2687–93.
- [5] Kondoh H, Yamada T, Yoshida A, Arima R, Hatsuoka S, Shintani H. Rapid development of a papillary fibroelastoma in the aortic valve: report of a case. Surg Today 2009;39: 713–6.
- [6] Joffe II, Jacobs LE, Owen AN, Ian I, Ioli A, Kotler MN. Rapid development of a papillary fibroelastoma with associated thrombus: the role of transthoracic and transesophageal echocardiography. Echocardiography 1997;14:287–92.
- [7] Wittersheim M, Heydt C, Hoffmann F, Büttner R. KRAS mutation in papillary fibroelastoma: a true cardiac neoplasm? J Pathol Clin Res 2017;3:100–4.
- [8] Shaian DM, Labib SB, Chang G. Cardiac papillary fibroelastoma. Ann Thorac Surg 1995; 59:538–41.
- [9] Gowda RM, Khan IA, Nair CK, Mehta NJ, Vasavada BC, Sacchi TJ. Cardiac papillary fibroelastoma: a comprehensive analysis of 725 cases. Am Heart J 2003;146:404–10.